Linked Life Data

12703211

Source:http://linkedlifedata.com/resource/pubmed/id/12703211

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2003-4-21
pubmed:abstractText
The approval by the FDA of ONTAK (DAB389IL2) for CTCL and the encouraging results described above with a number of DT conjugates for different neoplasms suggest that a niche is developing for these biologic agents. Moreover, practicing physicians are becoming more familiar with the side effect profile for these agents, increasing their comfort with using these unique drugs. Finally, the marked synergy observed between standard cytotoxic drugs and other biologics such as Herceptin and Rituximab suggests that similar supra-additive effects may be observed by combining DT conjugates with chemotherapy. In support of this hypothesis, in vitro synergy has been observed between DT388GMCSF and both cytarabine and doxorubicin [84,85]. The future appears to show expanded testing of DT conjugates with likely rapid clinical development, particularly for chemotherapy-resistant hematologic neoplasms and brain tumors.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0921-4410
pubmed:author
pubmed:issnType
Print
pubmed:volume
20
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
301-13
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
2002
pubmed:articleTitle
Diphtheria toxin conjugate therapy of cancer.
pubmed:affiliation
Wake Forest University School of Medicine, Medical Center Drive, Winston-Salem, NC 27157, USA. afrankel@wfubmc.edu
pubmed:publicationType
Journal Article, Review